• Deutsch
Login

Open Access

  • Home
  • Search
  • Browse
  • Publish
  • FAQ

Refine

Author

  • Bickel, Markus (1)
  • Bodtländer, Alexander (1)
  • Klauke, Stefan (1)
  • Knecht, Gaby (1)
  • Kurowski, Michael (1)
  • Lutz, Thomas (1)

Year of publication

  • 2008 (1)

Document Type

  • Article (1)

Language

  • English (1)

Has Fulltext

  • yes (1)

Is part of the Bibliography

  • no (1)

Institute

  • Medizin (1)

1 search hit

  • 1 to 1
  • 10
  • 20
  • 50
  • 100
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients (2008)
Bickel, Markus ; Bodtländer, Alexander ; Knecht, Gaby ; Kurowski, Michael ; Klauke, Stefan ; Lutz, Thomas
Poster presentation: Background In the past years, once-daily (QD) dosing of antiretroviral combination therapy has become an increasingly available treatment option for HIV-1+ patients. Methods Open label study in which HIV-1+ patients treated with SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-RNA-PCR < 50 copies/ml were switched to SAQ/RTV(2000/100 mg QD) with unchanged NRTI-backbone. CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and metabolic parameters were compared. Summary of results 17 patients (15 male, 42 years), median CD4 456 ± 139/micro l were included so far. The median follow-up time is 4 months. The HIV-RNA-PCR remained <50 copies/ml for all patients. Fasting metabolic parameters remained unchanged. The SAQ AUC 0–12 h were significantly higher when given QD vs. BID (median 29,400 vs. 18,500 ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC was lower for RTV when given QD vs. BID (7,400 vs. 11,700 ng*h/ml; p = 0.02). Conclusion In this ongoing study SAQ/RTV (2000/100 mg QD) was well tolerated and demonstrated higher SAQ and lower RTV drug levels as compared to the BID dosing schedule. (Table 1 and Figure 1.)
  • 1 to 1

OPUS4 Logo

  • Contact
  • Imprint
  • Sitelinks